Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023)
Genelux's (GNLX) quarterly Total Non-Current Liabilities came in at $1.9 million in Q4 2023, down 80.74% year-on-year from $9.7 million in Q4 2022, and up 44.76% quarter-over-quarter from $1.3 million in Q3 2023.
Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Genelux's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.9 million for Q4 2023.
- On a quarterly basis, Total Non-Current Liabilities fell 80.74% year-over-year to $1.9 million in Q4 2023; TTM through Dec 2023 was $1.9 million, a 80.74% decrease from a year earlier, with the FY2023 full-year figure at $1.9 million, down 80.74% from the prior year.
- Total Non-Current Liabilities climbed to $1.9 million in Q4 2023 per GNLX's latest filing, from $1.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.7 million in Q4 2022 and bottomed at $1.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Dec 31, 2022 | 9.69 Mn |